丹红注射液治疗急性脑梗死的临床疗效和安全性分析  

Clinical Efficacy and Safety Analysis of Danhong Injection in Treating Acute Cerebral Infarction

作　　者：曹宇晶 黄欢欢[1] 段丹辉[1] 宋宇[1] 王宇微[1] CAO Yujing;HUANG Huanhuan;DUAN Danhui(The First Affiliated Hospital of Harbin Medical University,Heilongjiang Harbin 150001, China)

机构地区：[1]哈尔滨医科大学附属第一医院神经内科,黑龙江哈尔滨150001

出　　处：《河北医学》2019年第4期676-679,共4页Hebei Medicine

基　　金：黑龙江省卫生厅科研基金项目;(编号:2014JM40271)

摘　　要：目的:探讨丹红注射液治疗急性脑梗死的临床疗效和安全性。方法:收集2015年1月至2017年10月入院的300例急性脑梗死患者随机分为两组,传统组患者给予西医综合治疗,联合组患者则加用丹红注射液,比较两组患者主要症状、总体治疗效果、凝血、内皮功能与安全性。结果:联合组患者治疗后主要症状总分组间比较显著性低于传统组;总有效率均显著性高于传统组;治疗后PT、APTT、6-keto-PGF1α与NO水平组间比较均显著性高于传统组,Fib、D-二聚体、ET-1与TXB2水平均显著性低于传统组,存在显著性差异(P<0.01);两组患者治疗后血液指标、肝功与肾功指标不存在明显差异(P>0.05)。结论:丹红注射液治疗急性脑梗死的临床疗效显著,安全性较高,具有借鉴意义。Objective: To investigate the clinical efficacy and safety of Danhong injection in the treatment of acute cerebral infarction. Methods: 300 patients with acute cerebral infarction who were hospitalized from January 2015 to October 2017 were randomly divided into two groups. Patients in the traditional group were treated with western medicine combined with Danhong injection. Patients in the two groups were compared Symptoms, overall treatment, coagulation, endothelial function and safety. Results: After treatment, the main symptoms in the combined group were significantly lower than those in the traditional group. The total effective rate was significantly higher than that in the traditional group. After treatment, the levels of PT, APTT, 6-keto-PGF1α and NO were significantly different The levels of Fib, D-dimer, ET-1 and TXB2 were significantly lower than those in the traditional group (P<0.01). The blood parameters, liver function and kidney There is no significant difference between the power indicators (P>0.05). Conclusion: Danhong injection has significant clinical effect and high safety in the treatment of acute cerebral infarction.

关 键 词：丹红注射液 急性脑梗死 总体治疗效果 安全性 

分 类 号：R277.7[医药卫生—中医学]